Dr Shallis on the Utility of Luspatercept in the ELEMENT-MDS Trial in MDS
Vložit
- čas přidán 9. 09. 2024
- Rory Shallis, MD, assistant professor, medicine (hematology), Yale School of Medicine, Yale New Haven Health, discusses the utility of luspatercept-aamt (Reblozyl) as evaluated in the phase 3 ELEMENT-MDS trial (NCT05949684) for patients with myelodysplastic syndrome (MDS).
Website: www.onclive.com
Twitter: / onclive
Facebook: / onclive
LinkedIn: / onclive